Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Tocilizumab in Chinese Patients With Systemic Juvenile Idiopathic Arthritis
NCT03301883Phase 4Completed
- Sponsor
- Roche
- Start
- Apr 2018
- Primary completion
- Sep 2021
- Modality
- Antibody Conjugates, Recombinant Proteins and Enzymes, Engineered Antibody Formats
- Countries
- 1
01
Overview
A Phase 4 trial of tocilizumab in systemic juvenile idiopathic arthritis (SJIA), sponsored by Roche. Started Apr 2018; status: completed.
02
Drugs
tocilizumab
03
Conditions
systemic juvenile idiopathic arthritis (SJIA)
Beyond the preview
Go deeper on NCT03301883.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03301883.